J&J Thinks It Can Win Over Biosimilar Competition
Executive Summary
The big pharma reports strong 2Q earnings and executives talk about strategy for defending against biosimilar competition in the US.
You may also be interested in...
Nixed Remicade Patent Clears Way For Pfizer/Celltrion Biosimilar Launch
A Massachusetts court's ruling invalidating a patent on Johnson & Johnson's Remicade (infliximab) appears to clear the way for Pfizer Inc. and Celltrion Inc. to finally launch their FDA-licensed biosimilar Inflectra (infliximab-dyyb). J&J, however, said it plans to appeal and any biosimilar launch would be considered "at risk."
Nixed Remicade Patent Clears Way For Pfizer/Celltrion Biosimilar Launch
A Massachusetts court's ruling invalidating a patent on Johnson & Johnson's Remicade (infliximab) appears to clear the way for Pfizer Inc. and Celltrion Inc. to finally launch their FDA-licensed biosimilar Inflectra (infliximab-dyyb). J&J, however, said it plans to appeal and any biosimilar launch would be considered "at risk."
Samsung Seeks Third Anti-TNF Biosimilar Launch In Europe
After receiving regulatory approvals in Europe for its biosimilar versions of etanercept and infliximab earlier this year, South Korea's Samsung Bioepis is now looking to add adalimumab to it and partner Biogen’s growing portfolio.